Brandon Vazquez

Hogan characterized North America as stable and no better or worse; Morici explained guidance uses most recent order flow.

John said direct Middle East business impact is small; concern is indirect through higher fuel prices, inflation, and share-of-wallet competition. Resin costs mitigated by fixed contracts. Financing tools (HFD) continue to address affordability.

Joe described two growth vectors: deeper penetration within existing DSOs and recruitment of new DSO partners attracted by Align's ability to scale treatment planning, distribution, and product portfolio.

John confirmed guidance assumes no market improvement, just continuation of H2 2025 trends with Align executing its active conversion approach and portfolio strategy. Not expecting markets to do anything different.

Joe attributed teen growth to China seasonality, IPE/MAOB product expansion enabling earlier starts, plus breadth across Europe and emerging economies. Did not directly declare wires-and-brackets regression over.

John quantified DSOs at ~25% of total business. Durability implied by structural advantages (digital workflows, scanning, financing, competitive pricing) but not explicitly promised.

Joe highlighted breadth of growth across regions, product lines, and patient segments (teens and adults), plus iTero Lumina restorative launch as tailwind.

Joe described IPE adoption tracking Invisalign First trajectory, with synergistic effects between the two products. Now expanding from regional to global.

Joe attributed international strength to a mix of penetration opportunities, better macro conditions, and new technology rollouts creating expansion in established markets.

Fred downplayed major portfolio changes, hinting at possible pruning and disciplined, highly strategic M&A, with a long-term vision to be a practice-improvement platform.

Ron acknowledged more insured patients is generally better for the medical business but said ACA/Medicaid changes are not having a material impact and represent a relatively small part of customers' business.

Stanley described medical as relatively stable with some respiratory headwinds but home care business unaffected by legislation. On tariffs, management anticipates passing through increases if needed while continuing alternative sourcing, considers flat 15% manageable.

Stanley explained KKR initiated the request based on appreciation of the company after studying dental for over a decade. Board approved based on substance, not specific promises. KKR Capstone helped select consulting firms, provided indirect procurement relationships, and two board members are actively contributing.

Ron confirmed organic growth expectations are unchanged from initial guidance, implying that FX improvement offsets other puts and takes rather than raising the organic growth outlook.

Stanley described DSOs as stable to positive, with few if any in financial difficulty. Noted they have adjusted to higher interest rates both for debt servicing and expansion investment.

Stanley confirmed near-complete dental consumable coverage with corporate brands, noting gaps only in traditional equipment and generic pharmaceuticals, with a hybrid branded/corporate model.

Ron clarified that compensation comments referred to management incentive comp, not sales commissions, though some sales commission changes were made to drive growth and margins.

Kristin clarified list price is unchanged; Wetteny cited the persistence of macro/competitive pressure plus ~$60-65M top-line and ~$30M bottom-line incremental FX headwinds.

Kristin pushed back firmly, stating she does not expect generics in major therapeutic areas, that price-driven promotions will stabilize, and that innovation and service differentiation will endure.

Wetteny outlined cadence: H1 faces tougher comps from strong H1 2025, Librela year-over-year comps remain strong in H1, and delayed US JAK launch extends competitive promotional window further into 2026.

Kristin attributed visit softness primarily to cumulative vet clinic price increases over three years rather than declining demand. Pet owners still bring sick pets in; demand is there. Vets focused on providing better value. New operating models emerging. Expects improvement through 2026.

Kristin outlined approach: start with specialists before general vets, raise OA awareness as progressive disease, invest in Phase IV research. Lenivia is a different molecule targeting different NGF location at 10x lower dose with 3-month duration. Portela expected to expand cat market by reducing monthly visit barrier.

Kristin said vets want more data to support conversations with pet owners. Focused on vet education, third-party studies, and European KOL engagement. Over 75% of US patients report being extremely or very satisfied.

Kristin reiterated major market approval expected every year for next few years. Near-term: long-acting OA pain for dog and cat. 12-36 months: long-acting Cytopoint, renal ($3-4B TAM), oncology ($1.5B+ TAM).

Kristin acknowledged small pockets of measured consumer behavior on chronic conditions but highlighted portfolio breadth, strong wellness growth, and animal health's recession-resistant nature.

Andrew confirmed CAG recurring guide midpoint of 9% for 2026 (+100bps vs 2025) is largely volume-driven through customer base expansion and utilization growth. FNA controlled launch captured in outlook. InVue corporate placements now underway. 5,500 InVue placements targeted for 2026. Cautious on macro/clinical visit assumptions at ~2% decline.

Jay confirmed Velo users see fewer no-shows, more diagnostic usage, and higher visit volumes. Cloud-based PIMS placements growing double-digits, now a leader in North American cloud PIMS. Software still relatively small vs total diagnostics installed base but growing. Andrew noted solid double-digit software recurring revenue growth in Q4.

Jay confirmed Cancer Dx is opening doors with competitive lab customers, providing opportunity to reintroduce the broader IDEXX Reference Lab portfolio. Described it as an important but not sole piece of the competitive strategy.

Andrew declined to comment on April visit metrics but noted Q2 midpoint CAG recurring revenue of ~6.25% is in line with days-adjusted Q1. Frequency and utilization remain resilient growth drivers.

Jake described goal of removing friction across entire patient journey from awareness to service. Software features go through appropriate clinical pathways including 510(k). Delayed high alert cited as example of clinically validated competitive differentiator. Working with administration on faster innovation pathways.

Jereme confirmed analyst ballpark of $1,400-$1,500 annual revenue per patient not far off. Channel-by-channel pricing impact typically 2-3% YoY. Primary headwind is mix from pharmacy channel growth, which has been stabilizing. Potential CMS T2 non-insulin coverage could swing mix back toward DME.

Jereme confirmed monthly reimbursement approach for 15-day sensor same as 10-day. Revenue per time period expected to remain the same across all business lines. Approach consistent with CMS monthly rental basis model.

Mick did not break out Americas devices by quarter; framed the market at mid-single-digit growth as a floor to meet-and-beat, citing China and Asia-Pac AirCurve launches for ROW.

Management highlighted N30i, F30i family, AirSense 11 geographic rollout (LatAm, China), and hinted at algorithmic/AI upgrades. CFO confirmed margin leverage continuation into FY2027.

Mick highlighted CME as #1 downloaded PCP training, up 50% quarter-over-quarter to 60,000 completions. PCPs learning gold standard pathways and connecting to home sleep apnea testing services. Not yet quantifying exact referral conversion but seeing results.